Should We Genetically Modify Our Children?
By Jessica Cussins,
Kennedy School Review
| 12. 07. 2015
Now that we have the power to permanently alter humanity, should we?
This was the question at the heart of the International Summit on Human Gene Editing in Washington, D.C., last week, an event co-hosted by the U.S. National Academy of Sciences and of Medicine, the Chinese Academy of Sciences, and the U.K.’s Royal Society. For three days, hundreds of scientists, scholars, and public interest advocates (and thousands others online and at #GeneEditSummit) discussed the scientific, social, ethical, and legal considerations posed by the prospect of making alterations to the human genetic code.
The summit was set in motion with the advent of a new gene-editing technology known as CRISPR. The technique was discovered just three years ago, more than a decade after other gene-editing technologies. Unlike previous methods, CRISPR is cheap and easy to use, and caused an explosion in research and interest. The U.S. National Institute of Health invested more than $80 million in CRISPR in 2014, and nearly 600 papers about the new technique were published by the end of that year.
All of the potential...
Related Articles
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
Alice Wong, founder of the Disability Visibility Project, MacArthur Genius, liberationist, storyteller, writer, and friend of CGS, died on November 14. Alice shone a bright light on pervasive ableism in our society. She articulated how people with disabilities are limited not by an inability to do things but by systemic segregation and discrimination, the de-prioritization of accessibility, and the devaluation of their lives.
We at CGS learned so much from Alice about disability justice, which goes beyond rights...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...